145 related articles for article (PubMed ID: 36879168)
1. Improving pharmacological activities of thrombopoietin mimetic peptide by genetic fusion to albumin-binding domain.
Li D; Gao G; Zhu B; Ying J
Biotechnol Lett; 2023 Apr; 45(4):439-448. PubMed ID: 36879168
[TBL] [Abstract][Full Text] [Related]
2. Functional expression of human serum albumin-tandem thrombopoietin mimetic peptide fusion protein as a novel thrombopoietin analog in Pichia pastoris.
Wang M; Zhi D; Xian J; Ru Y; Wei S; Wang N; Liu Y; Wang H; Pei Y; Song M; Li Y; Li H
Biotechnol Lett; 2016 May; 38(5):779-85. PubMed ID: 26857608
[TBL] [Abstract][Full Text] [Related]
3. Expression and bioactivity of recombinant human serum albumin and dTMP fusion proteins in CHO cells.
Ru Y; Zhi D; Guo D; Wang Y; Li Y; Wang M; Wei S; Wang H; Wang N; Che J; Li H
Appl Microbiol Biotechnol; 2016 Sep; 100(17):7565-75. PubMed ID: 27115755
[TBL] [Abstract][Full Text] [Related]
4. Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo.
Ren Z; Zhao J; Cao X; Wang F
Protein Expr Purif; 2022 Dec; 200():106147. PubMed ID: 35917982
[TBL] [Abstract][Full Text] [Related]
5. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
[TBL] [Abstract][Full Text] [Related]
6. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
[TBL] [Abstract][Full Text] [Related]
7. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
8. Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein.
Gapizov SS; Petrovskaya LE; Shingarova LN; Kryukova EA; Boldyreva EF; Lukashev EP; Yakimov SA; Svirshchevskaya EV; Dolgikh DA; Kirpichnikov MP
Biotechnol Appl Biochem; 2019 Jul; 66(4):617-625. PubMed ID: 31140614
[TBL] [Abstract][Full Text] [Related]
9. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
[TBL] [Abstract][Full Text] [Related]
10. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
11. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
[TBL] [Abstract][Full Text] [Related]
12. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.
Andersen JT; Pehrson R; Tolmachev V; Daba MB; Abrahmsén L; Ekblad C
J Biol Chem; 2011 Feb; 286(7):5234-41. PubMed ID: 21138843
[TBL] [Abstract][Full Text] [Related]
13. Rational and efficient preparation of a chimeric protein containing a tandem dimer of thrombopoietin mimetic peptide fused to human growth hormone in Escherichia coli.
Wang S; Shen M; Xu Y; Chen F; Chen M; Chen S; Wang A; Zhang Z; Ran X; Cheng T; Su Y; Wang J
Appl Microbiol Biotechnol; 2013 Apr; 97(7):2885-94. PubMed ID: 23149755
[TBL] [Abstract][Full Text] [Related]
14. Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity.
Lee JY; Park T; Hong E; Amatya R; Park KA; Park YH; Min KA; Jin M; Lee S; Hwang S; Roh GS; Shin MC
Biomaterials; 2020 Oct; 257():120250. PubMed ID: 32736262
[TBL] [Abstract][Full Text] [Related]
15. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.
Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z
Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653
[TBL] [Abstract][Full Text] [Related]
16. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
[TBL] [Abstract][Full Text] [Related]
17. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
[TBL] [Abstract][Full Text] [Related]
18. Purification and characterization of a long-acting ciliary neurotrophic factor via genetically fused with an albumin-binding domain.
Xu L; Zhang C; Liu L; Zhang Y; Wang Q; Wang J; Liu Y; Su Z
Protein Expr Purif; 2017 Nov; 139():14-20. PubMed ID: 28711730
[TBL] [Abstract][Full Text] [Related]
19. Half-life extension using serum albumin-binding DARPin® domains.
Steiner D; Merz FW; Sonderegger I; Gulotti-Georgieva M; Villemagne D; Phillips DJ; Forrer P; Stumpp MT; Zitt C; Binz HK
Protein Eng Des Sel; 2017 Sep; 30(9):583-591. PubMed ID: 29088432
[TBL] [Abstract][Full Text] [Related]
20. Extension of human GCSF serum half-life by the fusion of albumin binding domain.
Nikravesh FY; Shirkhani S; Bayat E; Talebkhan Y; Mirabzadeh E; Sabzalinejad M; Aliabadi HAM; Nematollahi L; Ardakani YH; Sardari S
Sci Rep; 2022 Jan; 12(1):667. PubMed ID: 35027593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
